Androgen receptor inducing bladder cancer progression by promoting an epithelial-mesenchymal transition

Andrologia

Volumn 46, Issue 10, 2014, Pages 1128-1133

  Jitao, W ^a   Jinchen, H ^a   Qingzuo, L ^a   Li, C ^a   Lei, S ^a   Jianming, W ^a   Zhenli, G ^a  

^a YANTAI YUHUANGDING HOSPITAL   (China)

Author keywords

Androgen receptor; Bladder cancer; Epithelial; Mesenchymal transition

Indexed keywords

ANDROGEN RECEPTOR; CADHERIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL; BLADDER TUMOR; CELL MOTION; CELL PROLIFERATION; DISEASE COURSE; DISEASE MODEL; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; TRANSITIONAL CELL CARCINOMA; TUMOR CELL LINE;

ANIMALS; CADHERINS; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; RECEPTORS, ANDROGEN; RNA INTERFERENCE; TRANSFORMING GROWTH FACTOR BETA; URINARY BLADDER NEOPLASMS;

EID: 84920279836     PISSN: 03034569     EISSN: 14390272     Source Type: Journal    
DOI: 10.1111/and.12203     Document Type: Article

References (24)

1. Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, Calin G, Wang H, Siefker-Radtke A, McConkey D (2009) miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clinical Cancer Res 15:5060-5072.
2. Birtle A, Freeman A, Munson P (2004) The androgen receptor revisited in urothelial carcinoma. Histopathology 45:98-99.
3. Colt JS, Baris D, Stewart P, Schned AR, Heaney JA, Mott LA, Silverman D, Karagas M (2004) Occupation and bladder cancer risk in a population-based case-control study in New Hampshire. Cancer Causes Control 15:759-769.
4. De Marzo AM, Nelson WG, Meeker AK, Coffey DS (1998) Stem cell features of benign and malignant prostate epithelial cells. J Urol 160:2381-2392.
5. Derynck R, Akhurst RJ (2007) Differentiation plasticity regulated by TGF-β family proteins in development and disease. Nature Cell Biol 9:1000-1004.
6. Fuchs IB, Lichtenegger W, Buehler H, Henrich W, Stein H, Kleine-Tebbe A, Schaller G (2002) The prognostic significance of epithelial-mesenchymal transition in breast cancer. Anticancer Res 22:3415.
7. Hara T, Miyazaki H, Lee A, Tran CP, Reiter RE (2008) Androgen receptor and invasion in prostate cancer. Cancer Res 68:1128-1135.
8. Hempel N, Ye H, Abessi B, Mian B, Melendez JA (2009) Altered redox status accompanies progression to metastatic human bladder cancer. Free Radical Biol Med 46:42-50.
9. Jacobs BL, Lee CT, Montie JE (2010) Bladder cancer in 2010: how far have we come? CA Cancer J Clin 60:244-272.
10. Johnson AM, O'Connell MJ, Miyamoto H, Huang J, Yao JL, Messing EM, Reeder JE (2008) Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospondin-1. BMC Urology 8:7.
11. Koo V, El Mekabaty A, Hamilton P, Maxwell P, Sharaf O, Diamond J, Watson J, Williamson K (2010) Novel in vitro assays for the characterization of EMT in tumourigenesis. Analyt Cell Pathol 32:67-76.
12. Li Y, Yang X, Su LJ, Flaig TW (2010) VEGFR and EGFR inhibition increases epithelial cellular characteristics and chemotherapy sensitivity in mesenchymal bladder cancer cells. Oncol Rep 24:1019-1028.
13. Madeb R, Messing EM (2004) Gender, Racial and Age Differences in Bladder Cancer Incidence and Mortality. Urol Oncol 22:86-92.
14. Makhsida N, Shah J, Yan G, Fisch H, Shabsigh R (2005) Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol 174:827-834.
15. Massagué J (2008) TGFβ in cancer. Cell 134:215-230.
16. Miyamoto H, Yang Z, Chen YT, Ishiguro H, Uemura H, Kubota Y, Nagashima Y, Chang YJ, Hu YC, Tsai MY (2007) Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst 99:558-568.
17. Peng CC, Chen KC, Peng RY, Su CH, Hsieh-Li HM (2006) Human urinary bladder cancer T24 cells are susceptible to the Antrodia camphorata extracts. Cancer Lett 243:109-119.
18. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. New Engl J Med 352:154-164.
19. Shen J, Wanibuchi H, Waalkes MP, Salim EI, Kinoshita A, Yoshida K, Endo G, Fukushima S (2006) A comparative study of the sub-chronic toxic effects of three organic arsenical compounds on the urothelium in F344 rats; gender-based differences in response. Toxicol Applied Pharm 210:171-180.
20. Taneja SS, Ha S, Swenson NK, Huang HY, Lee P, Melamed J, Shapiro E, Garabedian MJ, Logan SK (2005) Cell-specific regulation of androgen receptor phosphorylation in vivo. J Biol Chem 280:40916-40924.
21. Tang YQ, Han BM, Yao XQ, Hong Y, Wang Y, Zhao FJ, Yu SQ, Sun XW, Xia SJ (2008) Chimeric molecules facilitate the degradation of androgen receptors and repress the growth of LNCaP cells. Asian J Androl 11:119-126.
22. Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442-454.
23. Wu JT, Han BM, Yu SQ, Wang HP, Xia SJ (2010) Androgen receptor is a potential therapeutic target for bladder cancer. Urology 75:820-827.
24. Zhu ML, Kyprianou N (2010) Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells. FASEB J 24:769-777.